MX2009010193A - Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos. - Google Patents

Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.

Info

Publication number
MX2009010193A
MX2009010193A MX2009010193A MX2009010193A MX2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A MX 2009010193 A MX2009010193 A MX 2009010193A
Authority
MX
Mexico
Prior art keywords
nos
related compounds
tetrahydroquinoline
quinolone
inhibitory activity
Prior art date
Application number
MX2009010193A
Other languages
English (en)
Spanish (es)
Inventor
Shawn Maddaford
Jailall Ramnauth
Suman Rakhit
Joanne Patman
Paul Renton
Subhash C Annedi
Peter Dove
John Andrews
Sarah Silverman
Original Assignee
Neuraxon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010193(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxon Inc filed Critical Neuraxon Inc
Publication of MX2009010193A publication Critical patent/MX2009010193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009010193A 2007-03-23 2008-03-25 Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos. MX2009010193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89682907P 2007-03-23 2007-03-23
PCT/CA2008/000569 WO2008116308A1 (en) 2007-03-23 2008-03-25 Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity

Publications (1)

Publication Number Publication Date
MX2009010193A true MX2009010193A (es) 2009-12-15

Family

ID=39775375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010193A MX2009010193A (es) 2007-03-23 2008-03-25 Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.

Country Status (14)

Country Link
US (1) US8173813B2 (enExample)
EP (1) EP2139886A4 (enExample)
JP (1) JP2010521527A (enExample)
CN (1) CN101679397A (enExample)
AR (1) AR065845A1 (enExample)
AU (1) AU2008232269A1 (enExample)
CA (1) CA2681771A1 (enExample)
CL (1) CL2008000838A1 (enExample)
IL (1) IL201142A (enExample)
MX (1) MX2009010193A (enExample)
NZ (1) NZ580618A (enExample)
TW (1) TWI417099B (enExample)
WO (1) WO2008116308A1 (enExample)
ZA (1) ZA200907458B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CA2738405A1 (en) * 2008-09-29 2010-04-01 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
FR2984323B1 (fr) * 2011-12-16 2019-08-30 L'oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
WO2014170902A1 (en) * 2013-04-17 2014-10-23 Ariel - University Research And Development Company, Ltd. Cb2 receptor ligands for the treatment of psychiatric disorders
JPWO2014208586A1 (ja) * 2013-06-26 2017-02-23 第一三共株式会社 三環性複素環化合物の製造方法
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN109206385B (zh) * 2017-07-03 2022-04-22 扬子江药业集团有限公司 一种地佐辛杂质a及其同系物的制备方法
FR3072286B1 (fr) 2017-10-13 2022-08-12 Oreal 7-amino-1,2,3,4-tetrahydroquinoleines particuliers, procede et composition
CN108853509A (zh) * 2018-05-03 2018-11-23 浙江大学 抑郁症的治疗和药物组合物
CN109053712A (zh) * 2018-09-19 2018-12-21 南京大学连云港高新技术研究院 一种2-氨基噻吩-3-羧酸甲酯衍生物c15h22n2o5s的合成方法
JP7527593B2 (ja) 2018-12-05 2024-08-05 ノースウェスタン ユニバーシティ 免疫治療用の神経型酸化物合成酵素阻害剤
AU2020407614A1 (en) * 2019-12-20 2022-08-18 The Jackson Laboratory Molecular targets for addiction
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022056736A1 (zh) * 2020-09-16 2022-03-24 中国科学院深圳先进技术研究院 左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用
CN115073370B (zh) * 2021-03-10 2024-12-17 成都硕德药业有限公司 新型烷基氨类化合物或盐、异构体、其制备方法及用途
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
WO2023177823A1 (en) * 2022-03-17 2023-09-21 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087561A (en) 1975-12-22 1978-05-02 Canada Packers Limited Control of nitrosamine formation in nitride cured meat with 1,2,3,4-tetrahydro-quinoline compounds
FR2358151A1 (fr) * 1976-03-31 1978-02-10 Roussel Uclaf Nouvelles benzazepines et leurs sels, procede de preparation et application a titre de medicaments
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
NL8103769A (nl) 1980-08-12 1982-03-01 Glaxo Group Ltd Heterocyclische verbindingen, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4710507A (en) 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
ATE138658T1 (de) * 1987-12-30 1996-06-15 Orion Yhtymae Oy Heterocyclische verbindungen
US4963677A (en) * 1987-12-30 1990-10-16 Orion Corporation Ltd. Heterocyclic lactam compounds
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
JPH09504028A (ja) * 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
KR100423272B1 (ko) * 1994-02-03 2004-09-01 캠브리지 뉴로사이언스, 인코포레이티드 신경전달물질의방출을조절하는화합물,이의약학적으로허용가능한염및이를포함하는약학조성물
EP0759027B1 (en) * 1994-05-07 1999-08-04 Astra Aktiebolag Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
HUP9904215A3 (en) * 1996-11-25 2002-01-28 Procter & Gamble 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
CA2272640C (en) * 1996-11-25 2003-07-08 The Procter & Gamble Company Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
JPH10265450A (ja) * 1997-03-25 1998-10-06 Mitsui Chem Inc 一酸化窒素合成酵素阻害作用を有する新規なアミジン誘導体
SE9701682D0 (sv) * 1997-05-05 1997-05-05 Astra Ab Compounds
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CA2447687A1 (en) * 2001-05-16 2002-12-19 Antexpharma, Inc. Substituted 1-benzazepines and derivatives thereof
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
CA2370751A1 (en) * 2002-02-05 2003-08-05 Garth B.D. Shoemaker Fast and accurate rendering of pliable display technology distortions using pre-calculated texel coverages
WO2003076405A1 (en) * 2002-03-14 2003-09-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
US20050171195A1 (en) * 2003-11-06 2005-08-04 Carroll William A. P2X7 antagonists for treating neuropathic pain
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
AU2006277684A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual NOS inhibitory activity and muopioid agonist activity
AU2006268713A1 (en) 2005-07-13 2007-01-18 F. Hoffmann-La Roche Ag Benzimidazole derivatives as 5-HT6,5-HT24

Also Published As

Publication number Publication date
ZA200907458B (en) 2011-01-26
US20080234237A1 (en) 2008-09-25
US8173813B2 (en) 2012-05-08
EP2139886A4 (en) 2011-03-30
JP2010521527A (ja) 2010-06-24
CA2681771A1 (en) 2008-10-02
NZ580618A (en) 2012-07-27
TW200902003A (en) 2009-01-16
IL201142A (en) 2013-12-31
CN101679397A (zh) 2010-03-24
EP2139886A1 (en) 2010-01-06
CL2008000838A1 (es) 2008-10-10
WO2008116308A1 (en) 2008-10-02
TWI417099B (zh) 2013-12-01
AR065845A1 (es) 2009-07-08
AU2008232269A1 (en) 2008-10-02
IL201142A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
MX2009010193A (es) Quinolona y tetrahidroquinolina y compuestos relacionados que tienen actividad inhibidora de nos.
MX2010005343A (es) Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
NZ590727A (en) Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
WO2014055996A3 (en) Rho kinase inhibitors
TR201909189T4 (tr) C-kit ki̇naz i̇nhi̇bi̇törü bi̇leşi̇kler ve bi̇leşi̇mler
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
WO2008057691A3 (en) Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
WO2009067607A3 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
EP3341034A4 (en) ANTIMICROBIAL AND ENZYME-INHIBITING ZINC OXIDE NANOPARTICLES
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EP4385576A3 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2010081662A3 (en) Methods for identifying patients who will respond well to cancer treatment
PH12022551392A1 (en) Antibacterial quinolines
TW200638937A (en) Use of EGFR tyrosinekinase inhibitors for treatment of chronic rhinosinusitis
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders

Legal Events

Date Code Title Description
FG Grant or registration